ARM's Regen Med & Advanced Therapies State of the Industry Briefing January 11

About the Briefing
ARM's Annual Regen Med & Advanced Therapies State of the Industry Briefing is a top-level gathering for key stakeholders in the sector - including business executives, investors, patient advocates and academic leaders - to learn more on the recent progress and outlook for the industry in the coming year. This event annualy attracts over 300 attendees and is the largest gathering specifically for regenerative medicine and advanced therapies taking place during JP Morgan week in San Francisco.
Attendance
This Briefing is free to attend and open to the public - RSVP is required below. Please note this Briefing is held in conjunction with EBD's Biotech Showcase. Therefore, anyone not registered for the full Biotech Showcase conference will be asked to leave the meeting area immediately following the close of this Briefing.
Program Agenda
8:00am - 8:20am | Program Introduction & Industry Update
Edward Lanphier, President & CEO, Sangamo BioSciences; Chairman, Alliance for Regenerative Medicine
Morrie Ruffin, Managing Director, Alliance for Regenerative Medicine
8:20am - 9:05am | The 2016 Sector Forecast: Upcoming Clinical Data Events
This session features CEOs and senior executives from leading companies in the regenerative medicine and advanced therapies sector for a forward-looking discussion of expected clinical data events in 2016 and beyond. Panelists will address key issues related to continuing momentum in the sector as well as unique strategies and partnerships that will be required for success going forward.
Jason Kolbert, Head of Healthcare Research & Senior Managing Director, Maxim Group (co-moderator)
Jason McCarthy, Equity Research Analyst, Biotechnology, Maxim Group (co-moderator)
Eduardo Bravo, CEO, TiGenix
Silviu Itescu, Managing Director & CEO, Mesoblast
Sven Kili, VP & Head of Gene Therapy Development, GlaxoSmithKline
Jeffrey Walsh, COO, bluebird bio
Sue Washer, President & CEO, AGTC
9:05am - 9:50am | The Promise of Regenerative Medicine & Advanced Therapies in Oncology
This in-depth session will examine the progress of regenerative medicine and advanced therapies specifically as the field relates to the area of oncology. The panel's expert speakers will discuss a number of key hurdles on the path to commercialization including reimbursement and market access and what progress can be expected in the sector in the coming year.
Joshua Schimmer, Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
Usman Azam, Global Head, Cell & Gene Therapies Unit, Novartis
André Choulika, Chairman & CEO, Cellectis
Gregg Sando, Founder & CEO, Cell Medica
9:50am | Program End
Who Attends?
Over 300 of the advanced therapy and regenerative medicine field's top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector's recent advances and outlook for the industry in the coming year.
Location
Parc 55 Hotel
55 Cyril Magnin St.
San Francisco, CA 94102